2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163358
    SLC3037 99.85%
    SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases.
    SLC3037
  • HY-113466S
    4-Hydroxynonenal-d3 148706-06-3 ≥99.0%
    4-Hydroxynonenal-d3 is the deuterium labeled 4-Hydroxynonenal. 4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of acetaldehyde dehydrogenase 2 (ALDH2). 4-Hydroxynonenal can modulate a number of signaling processes mainly through forming covalent adducts with nucleophilic functional groups in proteins, nucleic acids, and membrane lipids. 4-Hydroxynonenal plays an important role in cancer through mitochondria.
    4-Hydroxynonenal-d3
  • HY-W007511
    4-Methyl-1-pentanol 626-89-1 ≥98.0%
    4-Methyl-1-pentanol is a volatile aroma component of red wine, which is often used in the production and blending of wine. 4-Methyl-1-pentanol can also be used as an alcohol antagonist to antagonize the effects of ethanol and 1-butanol on cell-cell adhesion, and is used in the study of fetal alcohol syndrome.
    4-Methyl-1-pentanol
  • HY-W068682
    1-Hydroxyphenazine 528-71-2 99.80%
    1-Hydroxyphenazine (Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin) is an inhibitor for α-Amylase with an IC50 of 3.1 μg/mL. 1-Hydroxyphenazine exhibits anticancer and anti-inflammatory activity against cells A549, 1321N1 and RAW264.7, antifungal and antibacterial activity against strains Candida albicans, Aspergillus fumigatus, Escherichia coli and Xanthomonas campestris.
    1-Hydroxyphenazine
  • HY-W069508
    3-(Aminomethyl)phenol 73604-31-6
    3-(Aminomethyl)phenol (m-Hydroxybenzylamine) reduces prefrontal Dopemine (DA) levels.
    3-(Aminomethyl)phenol
  • HY-W380450
    Viloxazine 46817-91-8 99.15%
    Viloxazine is a non-brain-penetrant, selective norepinephrine transporter (NET) inhibitor (IC50= 0.26 μM) and 5-HT receptor modulator. Viloxazine antagonizes 5-HT2B receptors (Ki=4.2 μM) and agonizes 5-HT2C receptors (EC50= 32 μM), respectively, and enhances 5-HT neurotransmission by modulating 5-HT2B/C receptors. Viloxazine also competitively inhibits NET from increasing NE and DA levels in the synaptic cleft, and can be used in the study of attention deficit hyperactivity disorder (ADHD).
    Viloxazine
  • HY-W741573
    N-Biotinyl p-aminophenyl arsenic acid 212391-23-6 98.13%
    N-Biotinyl p-aminophenyl arsenic acid is a bifunctional reagent that can bind to both streptavidin and dithiols. N-Biotinyl p-aminophenyl arsenic acid decreases the Rbungarotoxin-binding sites in reduced Torpedo nicotinic receptors (IC50 is 10-300 nM), and protects the receptor from irreversible alkylation by bromoacetylcholine.
    N-Biotinyl p-aminophenyl arsenic acid
  • HY-W013636S2
    2-Ketoglutaric acid-d6 1173021-86-7 98.62%
    2-Ketoglutaric acid-d6 (Alpha-Ketoglutaric acid-d6) is the deuterium labeled 2-Ketoglutaric acid (HY-W013636). 2-Ketoglutaric acid is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid is a reversible inhibitor of tyrosinase (IC50=15 mM).
    2-Ketoglutaric acid-d6
  • HY-132280
    Tirilazad 110101-66-1 98.11%
    Tirilazad is a nonglucocorticoid, 21-aminosteroid that inhibits lipid peroxidation. Tirilazad can attenuate brain or spinal cord injury caused by trauma, stroke, ischemia and reperfusion injury. Tirilazad has antiviral activities against nCoV. Tirilazad is neuroprotective for ischaemic stroke, can be used for subarachnoid hemorrhage research.
    Tirilazad
  • HY-100631
    FGFR4-IN-1 1708971-72-5 99.89%
    FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM.
    FGFR4-IN-1
  • HY-17412A
    Minocycline 10118-90-8 98.59%
    Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline
  • HY-12195
    ABT-239 460746-46-7 99.23%
    ABT-239 is a novel, highly efficacious, non-imidazole class of H3R antagonist and a transient receptor potential vanilloid type 1 (TRPV1) antagonist.
    ABT-239
  • HY-12844
    Ro 64-6198 280783-56-4 ≥99.0%
    Ro 64-6198 is a potent, selective, nonpeptide, high-affinity, high cellular permeability and brain penetration N/OFQ receptor (NOP) agonist with an EC50 value of 25.6 nM. Ro 64-6198 is at least 100 times more selective for the NOP receptor over the classic opioid receptors. Ro 64-6198 can be used for stress and anxiety, addiction, neuropathic pain, cough, and anorexia.
    Ro 64-6198
  • HY-13438
    AZD3839 free base 1227163-84-9 99.91%
    AZD3839 is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 can be used in the field of Alzheimer's disease research.
    AZD3839 free base
  • HY-17610
    Enerisant 1152747-82-4 99.79%
    Enerisant (TS-091) is a potent, highly selective, competitive and orally active histamine H3 receptor antagonist/inverse agonist with IC50s of 2.89 nM and 14.5 nM against human and rat histamine H3 receptors, respectively.
    Enerisant
  • HY-19958
    XEN907 912656-34-9 98.74%
    XEN907 is a potent and spirooxindole blocker of NaV1.7, with an IC50 of 3 nM. XEN907 also inhibits CYP3A4 in a recombinant human enzyme assay. XEN907 can be used for the research of pain.
    XEN907
  • HY-50883
    BMS 299897 290315-45-6 99.64%
    BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloid precursor protein (APP).
    BMS 299897
  • HY-B0161
    Duloxetine 116539-59-4 99.92%
    Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).
    Duloxetine
  • HY-B0189
    Mosapride 112885-41-3 99.87%
    Mosapride is an orally active gastroenterokinetic compound. Mosapride is a 5HT4 agonist. Mosapride is a CYP inducer. Mosapride has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride can be used in the study of gastrointestinal diseases.
    Mosapride
  • HY-100384
    NKL 22 537034-15-4
    NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC50 of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 exhibits selectivity over HDAC2/4/5/7/8 (IC50≥1.59 μM). NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
    NKL 22
Cat. No. Product Name / Synonyms Application Reactivity